Antitumor activity of ZD6474, a potent inhibitor of vascular endothelial growth factor signaling and epidermal growth factor, in the metastatic orthotopic brain tumor model

被引：0
作者：
Kong, Doo-Slk [1 ]
Jeon, Ji-Won [1 ]
Jeon, Hyun jung [1 ]
Nam, Do-Hyun [1 ]
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Neurosurg,Samsung Biomed Res Inst, Seoul, South Korea
来源：
CLINICAL & EXPERIMENTAL METASTASIS | 2007年 / 24卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：312 / 313
页数：2
相关论文
共 50 条
  • [21] ZD6474, a vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitor, inhibits growth of multiple primary central nervous system tumor types.
    Rich, JN
    Loncar, D
    Keir, S
    Wheeler, C
    Dimery, I
    Bigner, DD
    Friedman, HS
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6143S - 6143S
  • [22] A phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer (MBC)
    Miller, KD
    Trigo, JM
    Stone, A
    Wheeler, C
    Barge, A
    Sledge, GW
    Baselga, J
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S240 - S240
  • [23] Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer
    不详
    CLINICAL LUNG CANCER, 2005, 7 (02) : 89 - 91
  • [24] Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer
    Hanrahan, Erner O.
    Heymach, John V.
    CLINICAL CANCER RESEARCH, 2007, 13 (15) : 4617S - 4622S
  • [25] Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: Implications for use as a surrogate marker of antiangiogenic activity
    Beaudry, P
    Force, J
    Naumov, GN
    Wang, A
    Baker, CH
    Ryan, A
    Soker, S
    Johnson, BE
    Folkman, J
    Heymach, JV
    CLINICAL CANCER RESEARCH, 2005, 11 (09) : 3514 - 3522
  • [26] Antitumor treatment efficacy by targeting epidermal growth factor receptor and vascular endothelial growth factor receptor-2 in an orthotopic human glioblastoma model
    Yi, Diao
    Hua, Tian Xin
    Lin, Huang Yan
    Kui, Chen Lu
    Ning, Lin Xiao
    Wang, Zhuang Zai
    JOURNAL OF NEURO-ONCOLOGY, 2011, 104 (01) : 93 - 101
  • [27] Antitumor treatment efficacy by targeting epidermal growth factor receptor and vascular endothelial growth factor receptor-2 in an orthotopic human glioblastoma model
    Diao Yi
    Tian Xin Hua
    Huang Yan Lin
    Chen Lu Kui
    Lin Xiao Ning
    Zhuang Zai Wang
    Journal of Neuro-Oncology, 2011, 104 : 93 - 101
  • [28] ZD4190: An orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy
    Wedge, SR
    Ogilvie, DJ
    Dukes, M
    Kendrew, J
    Curwen, JO
    Hennequin, LF
    Thomas, AP
    Stokes, ESE
    Curry, B
    Richmond, GHP
    Wadsworth, PF
    CANCER RESEARCH, 2000, 60 (04) : 970 - 975
  • [29] ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model
    Matsurnori, Yuka
    Yano, Seiji
    Goto, Hisatsugu
    Nakataki, Emiko
    Wedge, Stephen R.
    Ryan, Anderson J.
    Sone, Saburo
    ONCOLOGY RESEARCH, 2006, 16 (01) : 15 - 26
  • [30] Prolonged exposure of colon cancer cells to the epidermal growth factor receptor inhibitor gefitinib(IressaTM)and to the antiangiogenic agent ZD6474:Cytotoxic and biomolecular effects
    Amalia Azzariti
    Letizia Porcelli
    Grazia Maria Simone
    Angelo Paradiso
    World Journal of Gastroenterology, 2006, (32) : 5140 - 5147
12345